VANIQA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vaniqa, and what generic alternatives are available?
Vaniqa is a drug marketed by Skinmedica and is included in one NDA.
The generic ingredient in VANIQA is eflornithine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eflornithine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VANIQA?
- What are the global sales for VANIQA?
- What is Average Wholesale Price for VANIQA?
Summary for VANIQA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 80 |
Clinical Trials: | 3 |
Patent Applications: | 4,579 |
Drug Prices: | Drug price information for VANIQA |
What excipients (inactive ingredients) are in VANIQA? | VANIQA excipients list |
DailyMed Link: | VANIQA at DailyMed |
Recent Clinical Trials for VANIQA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Children's Oncology Group | Phase 2 |
Bispebjerg Hospital | Phase 4 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for VANIQA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VANIQA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Skinmedica | VANIQA | eflornithine hydrochloride | CREAM;TOPICAL | 021145-001 | Jul 27, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VANIQA
See the table below for patents covering VANIQA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
New Zealand | 187536 | -SUBSTITUTEDALKYL- -HALOMETHYL- -AMINOACET- IC ACIDS | ⤷ Sign Up |
Australia | 4524393 | ⤷ Sign Up | |
Japan | S62500932 | ⤷ Sign Up | |
Spain | 2125339 | ⤷ Sign Up | |
Germany | 3585526 | ⤷ Sign Up | |
Israel | 54912 | ⤷ Sign Up | |
South Africa | 7803349 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |